Dr. Thomas Haverty has served as Chief Medical Officer since September 2019. Dr. Haverty has over 30 years of pharmaceutical and biotechnology experience leading clinical research and operations teams with responsibility for large development portfolios in virtually all classes of molecules and indications.
Dr. Haverty is a highly accomplished nephrologist and seasoned pharmaceutical executive with a demonstrated track record of successful development and approval of well over 20 leading drugs including Remicade, Clarinex, Peg-Intron, Nasonex, Keytruda and Zetia. Dr. Haverty shares our passion for the mission of bringing innovative novel medicines to patients who need them as quickly as possible.
Prior to joining Eloxx, Dr. Haverty had a long tenured successful career which began at Johnson & Johnson, after which Dr. Haverty moved to R&D leadership positions at Schering Plough and Merck Research Labs. Dr. Haverty brings expertise across a wide range of therapeutic categories, molecule types, dosage forms and technologies. Dr. Haverty is a Board-Certified Nephrologist with an M.D. in Internal Medicine from the University of California at San Diego, La Jolla, Ca. and dual B.S. degrees in Chemistry and Biology from Stanford University. Dr. Haverty has previously also served as Assistant Professor of Medicine at the University of Pennsylvania and Associate Professor of Medicine at the University of Alabama at Birmingham.